decreases INR, and the length of time which it maintains a decreased INR can be prolonged and unpredictable [2] . This can also make establishing a therapeutic INR on reinitiation of warfarin difficult. Fresh frozen plasma (FFP) is often used in conjunction with vitamin K in order to provide immediate reversal of warfarin. Use of FFP in VAD patients may be undesirable due to complications of large volume administration, pro-inflammatory cytokine release, allosensitization that can complicate or even preclude transplantation, and potential transfusion-related acute lung injury (TRALI) [3] . FFP is also limited in the degree to which it can lower INR, and may not lower INR adequately
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An Open Access Publisher for some procedures [4] . 4FPCC can decrease the INR more rapidly and decrease the risk of complications associated with plasma [5] . The effect of 4FPCC on the INR is transient due to the half life of the clotting factors and by precluding the need for interruption of warfarin. Because of this more transient effect on the INR, the use of 4FPCC may also prevent the need for a parentaral anticoagulation bridge back to a therapeutic INR post procedure, or at least allow for a shortened bridging course. The purpose of this case series is to describe the use of 4FPCC for decreasing INR in VAD patients undergoing invasive procedures at a tertiarycare academic medical center.
Patients and methods
This study was a retrospective review of 11 consecutive patients who had durable VADs and were administered 4FPCC (Kcentra) between May 2014 and October 2014. The inclusion criteria for the case series were 1. durable VAD, 2. documented warfarin reversal for a procedure other than heart transplant, 3. history of recent warfarin use and, 4. measurement of INR within 24 hours before and after 4FPCC administration. Patients 1 and 2 also received vitamin K near the time of 4FPCC administration and were analyzed separately. Patients were excluded if their first dose of 4FPCC was for bleeding, if they had not previously been on warfarin, and if there was not enough documentation to confirm 4FPCC administration. Eight separate 4FPCC administrations, each given to a unique patient, are the subject of this report. Patients were followed until INR returned to therapeutic threshold or for at least 90 hours. The medical records for the patients in the case series were examined for eligibility criteria and to describe therapy and its effect. The protocol was reviewed and approved by the Partners Healthcare System Institutional Review Board prior to data collection. Table 1 summarizes the demographic characteristics of the eight patients who met inclusion criteria. Patients 1 and 2 also received vitamin K. The mean patient age was 64.5 years (57-76 years). The majority of patients were male (87.5%). The most common type of VAD was the HeartMate II Left Ventricular Assist Device (LVAD) (50%), followed by Heartware (37.5%) and Thoratec Biventricular Assist Device (BiVAD) (12.5%). All patients were receiving aspirin doses ranging between 81mg (25%) and 325mg (62.5%) daily. Three patients in the 4FPCC-only group had warfarin held for one or more days prior to INR reversal (1-4 days). Liver function tests were normal for the majority of patients. However, 75% of patients had renal insufficiency with a mean serum creatinine of 1.38 mg/dL (range, 0.71-1.9 mg/dL). All eight of the patients had different invasive procedures including a peripherally inserted central catheter (PICC) placement, colonoscopy, VAD change-out, etc ( Table 1 ).
Results
The treatment characteristics of patients who received 4FPCC without vitamin K are described below. Patient 3 was discharged shortly after the procedure and sequential data for his INR is not available. Patients 6 and 7 received additional blood products (one patient received 3 bags of packed red blood cells (PRBC) and the other 2 bags of FFP and 1 bag of PRBC) within 48h of receiving 4FPCC. The specific indication for blood products was not clearly recorded in the patients' charts, however both patients had hematocrit drops prior to blood product administration. patients received 5mg of vitamin K. The average time for the INR to begin recovery post-reversal with vitamin K and 4FPCC was over 90h (Figure 2 ) compared to 34.1h in the 4FPCC-only group. The first patient had warfarin withheld for 3 days "prior and 2 days after 4FPCC administration," and reached a therapeutic INR 7 days after anticoagulation reversal. The second patient received FFP and had warfarin withheld for 4 days in addition to vitamin K and 4FPCC administration. A therapeutic INR was not achieved until 11 days after anticoagulation reversal. In the two patients who were given vitamin K, the average time to return to therapeutic INR was 8.5 days "after 4FPCC administration and 5.5 days after resuming warfarin," compared to 3.2 days "after 4FPCC administration and 2 days after resuming warfarin," in the group that received 4FPCC alone.
Discussion
The observations drawn from this case series suggest a faster recovery of therapeutic INR using 4FPCC alone for INR reversal prior to procedure without any observed safety events. There are currently no evidence-based guidelines for the use of 4PCC for warfarin reversal in patients with VADs. Current practice has significant variability regarding This is a small retrospective case series. Standard institutional practice did not exist for use of 4PCC to reverse warfarin peri-procedure in VAD patients at the time of this analysis. Duration of follow-up was short. No excess bleeding peri-procedure was observed with the use of this strategy. No cases of thrombotic events were observed during the study period, however we did not assess for events occurring 4 days after 4PCC adminstration.ration.
Conclusion
This case series demonstrates that 4FPCC alone for temporary anticoagulation reversal prior to invasive procedures in patients with VADs is a strategy that has the potential of providing patients and clinicians with a safe, effective, and rapid reversal of warfarin with quicker postreversal recovery compared with using concomitant vitamin K. Future studies should be directed towards evaluating standardized protocols, cost-effectiveness, hospital length of stay, time period of bridge therapy and subtherapeutic anticoagulation, and relationship to thrombotic.
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